Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Autoimmune Pancreatitis

Nagpal, Sajan Jiv Singh, MBBS1; Sharma, Ayush, MBBS1; Chari, Suresh T., MD1

American Journal of Gastroenterology: September 2018 - Volume 113 - Issue 9 - p 1301
doi: 10.1038/s41395-018-0146-0

Over the course of the last 2 decades our knowledge of autoimmune pancreatitis has increased exponentially. In this review, we summarize the clinical presentation, diagnosis and treatment of AIP, to better allow general gastroenterologists and primary care providers to consider AIP as a as a rare but important cause of painless obstructive jaundice and recurrent acute pancreatitis. While steroids remain the mainstay of first line therapy, a number of patients with type 1 AIP require immunomodulators or rituximab to maintain remission; recommendations on the management of relapses continue to evolve.

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Correspondence: S.T.C. (email:

Received 22 February 2018; accepted 4 May 2018; Published online 18 June 2018

© The American College of Gastroenterology 2018. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website